Background: To individualize timing of infliximab (IFX) treatment in children and adolescents with inflammatory bowel disease (IBD) using a patient-
C
hildren and adolescents with moderate-to-severe inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) can expect a disease course with intermittent periods of remission and relapse. A substantial number will need biological treatment over time. Several studies investigating infliximab (IFX) treatment in adults, [1] [2] [3] and a growing number of studies in pediatric patients, [4] [5] [6] [7] have shown IFX to be efficacious with regard to clinical response and remission. Pediatric patients may receive IFX maintenance treatment over long periods as a consequence of continuously active disease course, or specific pediatric complications such as growth retardation. [8] [9] [10] In standard practice, IFX induction is given in 3 treatments over 6 weeks, followed by maintenance treatment at eight-week intervals. 11, 12 However, some patients might benefit from a more individualized treatment approach. 4, 5, [13] [14] [15] To evaluate this, a carefully controlled and personalized medication of each patient is needed.
Personalized medicine, including self-management, is a new treatment approach being pursued for many chronic diseases, including IBD, 16 to improve disease control and empower patients. We have previously investigated patientmanaged eHealth to individualize the timing of IFX infusions in adults with CD 17 using the eHealth program www.constant-care. com. The key element of this eHealth program was an electronic traffic light system, which guided the scheduling of IFX treatment at intervals of 4 to 12 weeks. The traffic light system was based on patient-registered symptom scores and measures of fecal calprotectin (FC), combined into a total inflammation burden score (TIBS). The repeatedly measured TIBS formed a curve on a traffic light graph system consisting of the colors green, yellow, and red. Depending on the color, patients were advised regarding the timing of their next IFX treatment. The eHealth group was compared with a control group following the hospital's standard treatment guidelines, with treatment intervals of 8 weeks. The study showed that among eHealth patients, 39% had a shorter, and 50% a longer, interval than 8 weeks between treatments, thus representing an individualization of the treatment regimen. No increase in appearance of antibodies against IFX nor adverse events were observed. The inflammation burden during the intervention period was stable despite treatment intervals varying considerably.
The primary aim of this study was to investigate whether patient-managed eHealth, with a careful monitoring of symptoms and FC scores, could individualize the treatment intervals of IFX in children and adolescents with IBD. On the basis of the web resource www.constant-care.com, we developed a new eHealth program, www.young.constant-care.com, oriented toward pediatric and adolescent patients with IBD for this purpose. Patients given nonbiological treatment were included in a separate study of a different design and with an alternative eHealth resource. 18 In light of the novelty of the eHealth program, our secondary aims were to evaluate it for safety (development of IFX antibodies, infusion-related reactions, change of medication, and need for surgery) and its patient usability (eHealth adherence, Health-Related Quality of Life (HRQoL), patient evaluation, and dropout rate).
MATERIALS AND METHODS

Study Design and Patients
This was an open-label intervention study of a patientmanaged eHealth (web-based disease monitoring) solution to assist in scheduling IFX infusions. Eligible participants were children and adolescents (10-17 yr old), with UC or CD and on maintenance IFX treatment at the Department of Pediatrics, Hvidovre Hospital, Copenhagen University, Denmark.
Diagnoses of UC and CD were verified by the Porto criteria, based on a "combination of history, physical and laboratory examination, esophago-gastro-duodenoscopy and ileocolonoscopy with histology, and imaging of the small bowel." 19 Exclusion criteria were insufficient Danish language skills, no access to the Internet, low intellectual capacity, and perianal disease as the primary disease location. Eligible patients were invited to participate by letter or by their health care provider during regular consultations.
The study period took place from September 1, 2013 to April 31, 2016. Patients were consecutively recruited with a maximum follow-up of 2 years. The study was originally designed as an observational intervention study; however, it was expanded with a control group receiving standard IFX treatment 13 months after initiation of the study (October 1, 2014) to compare blood trough levels of IFX antibodies, IFX concentration, and treatment intervals. In standard care, the patients received IFX infusion every 8 weeks, but treatment intervals could be shortened to 7-, 6-, 5-, or 4-week intervals if needed, to gain control of the disease. Notably, the control group was FIGURE 1. The concept of www.young.constant-care.com and the algorithm behind the TIBS.
followed for a shorter period than the eHealth group. The period during which the control group was included will be referred to in the text as the control period. From the control group, the data obtained were the demographics, dates of treatments, and doses of IFX.
The extension of the eHealth program to children and adolescents, www.young.constant-care.com, based on the adult version, www.constant-care.com, has previously been described. 18 Briefly, the main differences of the young version as compared with the adult version are the incorporation of pediatric symptom scores (the abbreviated Pediatric Crohn's Disease Activity Index (abbrPCDAI) 20 and the Pediatric Ulcerative Colitis Activity Index (PUCAI) 21 ), resulting in a combination of FC levels in a new TIBS algorithm (Fig. 1) . Cutoff values for the abbrPCDAI and PUCAI for remission, mild, moderate, and severe disease activity follow the existing guidelines. 20, 21 A pediatric IBD HRQoL measure, IMPACT III, and measures of height and weight to ensure follow-up on growth were additionally incorporated in the pediatric version of the eHealth program.
Procedures eHealth
The eHealth program was used as an interactive tool for the patient and the IBD team. Patients received a personal username and a password. They were instructed individually in how to use the program for approximately 45 minutes, face to face, by the principal investigator, or an IBD nurse. Education was directed toward the patient but parents/caregivers were present during the session. Patients received automatically generated text message reminders through their mobile phone before each deadline for data entry and stool sample delivery. Parents could also choose to receive these reminders.
The TIBS (PUCAI/abbrPCDAI + FC) determined the interval between the IFX treatments. The treatment interval was limited to last from a minimum of 4 to a maximum of 12 weeks. Starting 4 weeks after the previous infusion, the patients registered PUCAI/abbrPCDAI weekly until their next IFX treatment. The same or the following day as the symptom score was entered, the patient submitted a fecal sample for the analysis of FC. The result of the FC analysis was available on the eHealth homepage after a short processing time (3-5 d) . The PUCAI/abbrPCDAI and FC levels were automatically combined to produce the TIBS (range 0-10) and visualized in the traffic light system for the patient (Fig. 1) . If the TIBS reached the yellow light for 2 consecutive weeks, or the red light just once, an appointment for treatment was scheduled within 1 to 5 days through phone contact with a parent. Patients with a green TIBS score would receive treatment before a maximum of 12 weeks had passed since their last infusion. Figure 2 illustrates 2 patient's course of TIBS and the timing of their IFX treatments.
Anytime alarm symptoms appeared (.6 stools per day, daily fresh blood in each defecation, fever, severe abdominal pain, or/and acute to severe exacerbation of symptoms), the families were instructed to consult the IBD team. In the infusion clinic, available infusion slots were kept free for the eHealth patients ensuring access to appointments with short notice.
Outcome Measures
Primary Outcome
Treatments. Individual treatment intervals were calculated to evaluate the ability of our eHealth program to facilitate personalization of IFX treatment. Date and dose of IFX infusions were prospectively registered from both the eHealth and the control groups.
Secondary Outcome
Safety. From participants in the eHealth trial and the control group, blood samples (10 mL) were taken before the IFX infusions to measure trough levels of IFX concentration and levels of antibodies. The results of the analyses were blinded for both the study staff and laboratory personnel. Samples were stored at 2808C and analyzed at the end of the trial, so as to prevent interfering with the eHealth treatment algorithm designed per protocol. IFX concentration and antibodies were measured by capture ELISA and antigen-bridging ELISA, respectively, using commercial kits according to the instructions from the manufacturer (Promonitor, Grifols, Barcelona, Spain).
Information regarding any infusion-related allergic reactions was obtained for the study from the patients' medical records. Changes in medication, nutritional therapy, and operations were likewise gathered.
Patient usability. The numbers of entries in the eHealth program, and FC samples delivered, was prospectively registered and compared with the expected counts to calculate patient adherence.
The HRQoL questionnaire, IMPACT III, 22, 23 was translated into Danish in cooperation with the Pediatric IBD Working Group of Quality of Life 23 through a "transcultural adaptation" method and was included in the www.young.constant-care program. The patients answered IMPACT III on the day of infusion and 4 weeks afterward. The IMPACT III consisted of 35 items covering the following domains: bowel symptoms, body image; emotional functioning, social functioning, tests/treatments, and systemic symptoms. Answers were given on a 5-point Likert scale, with a higher score representing a better HRQoL (range 35-175).
At the end of the trial, a patient-parent tandem evaluation questionnaire with a 5-point Likert scale, ranging from "completely agree" to "completely disagree," was completed. The questionnaire contained 5 domains: (1) improvement in control and management of their disease; (2) improvement in understanding and knowledge of their own/their child's disease; (3) feeling safe during the eHealth monitoring; (4) usability of the eHealth program; (5) parents' involvement.
Data Analysis
Demographic values, treatments, and blood samples were described by frequency (percent), median (range), and mean (SD). To account for the repeated measures, Mixed Effect Models (MEMs) were used to compare the eHealth and control groups regarding lengths of treatment intervals, IFX doses, and IFX trough concentrations. The association between IFX concentration and treatment intervals was also analyzed by MEM. Comparison of the number of patients developing antibodies to IFX was analyzed by Fisher's exact test. The first and final HRQoL score for each patient was compared using a paired t test. P values ,0.05 were considered as significant. Statistical analyses were performed using SAS Enterprise Guide 7.1 and R 3.2.2.
Ethical Issues
The trial was approved by the Danish Ethical Committee (Jr. H-2-2013-061) and the Danish Data Protection Agency (Jr. HVH-2014-004). It was registered on www.clinicaltrials.gov in May 2013 (ClinicalTrials.gov Identifier: NCT01860651). All patients and their guardians gave oral and written consent before their inclusion in the study.
RESULTS
Patient Population
During the study period, 29 patients (10 UC and 19 CD) were included in the eHealth study. The median follow-up was 553 days (IQ 217-696 d). In the control group, 21 patients were included (4 Table 1 , and follow-up data and dropout rates are given in Figure 3 .
Primary Outcome
Treatments
In total, 216 IFX treatments were given during the eHealth study. During the control period, 94 treatments were provided for the eHealth patients and 105 treatments for the control group.
During the total eHealth intervention, the mean treatment interval was 9.3 weeks (SD 1.9 wk). In the control period, the mean treatment interval in the eHealth group was 9.5 weeks (SD 2.3 wk), whereas in the control group it was 6.9 weeks (SD 1.4 wk). The distribution of all treatment intervals is shown in Figure 4 . During the control period, 23.4%/58.1% (eHealth/control) treatments were given at intervals of 8 weeks or fewer, 12.7%/ 37.1% were given at exactly 8-week intervals, and 64.9%/4.8% were given at 9-week intervals or more. We found a significant difference between treatment intervals (wk) for the eHealth group compared with the control group (MEM: estimate 2.35; 95% confidence interval [CI], 1.5-3.2; P-value , 0.001). Treatment intervals for each patient altered during their participation in the eHealth program. Each patient's treatment intervals during the study are presented in Table 2 .
The average IFX dose (mg/kg) per treatment did not differ between the eHealth and control groups during the control period (MEM: estimate 0.54; 95% CI, 20.36 to 1.43; P value 0.24).
Secondary Outcome
Safety IFX antibodies and concentration. From the eHealth group, 81 blood samples from 20 patients were collected, whereas from the control group 76 blood samples were collected from 21 patients. The median (min:max) number of blood samples per patient collected in the eHealth group was 4 (2:7), whereas in the control group it was 3 (1:7). The mean levels of concentration, stratified according to the length of treatment intervals, are presented in Table 3 .
We found a significant negative association between IFX concentration and length of treatment intervals (MEM: estimate 20.08; 95% CI, 20.14 to 20.03; P value 0.005), confirming that trough level of IFX concentration depends on the length of treatment intervals. We found a significant reduction in the trough IFX concentration in the eHealth group compared with the control group at baseline (MEM: estimate 23.48 95% CI, 26.63 to 20.33; P-value 0.03); however, after controlling for treatment intervals, the difference was reduced to a nonsignificant level (MEM: estimate 22.19 95% CI, 25.37 to 0.99; P-value 0.18).
There were 5 patients with a positive IFX antibody blood sample in the eHealth group and 2 in the control group (a total of 12 and 4 positive blood samples in the 2 groups). According to Fisher's exact test, the number of patients developing antibodies did not present a significant difference when comparing the eHealth and the control group (P value 0.24). Treatment intervals before the development of antibodies are presented in Table 4 . In all patients with positive antibodies, the IFX concentration was undetectable.
Five patients in the eHealth group and 12 patients in the control group had IFX trough levels .3 mg/mL at baseline. Of those, 4 (eHealth) and 9 (control) patients had IFX trough levels .7 mg/mL. During the control period, 2 patients in the eHealth group and 2 patients in the control group had a decrease in the IFX trough level from above 3 to below 3 mg/mL. Two (one eHealth and one control) of those patients who had a decrease in the IFX trough level developed antibodies (Table 4 : eHealth patient number 4 and control patient number 2).
Infusion-related reactions. In the eHealth group, 5 allergic reactions occurred during the 216 infusions, where 2 patients had a reaction twice and one patient had a single reaction; treatment intervals before infusion with reactions were ,8 weeks (7, 8, 6, 7, and 3 wk, respectively). IFX antibodies were found in the 2 patients with 2 reactions. A blood sample from the patient who experienced the one reaction was not available. In the control group, among 105 infusions, one patient had one allergic reaction. The treatment interval before this infusion was 6 weeks, and IFX antibodies were present.
Medication and operations. Two patients had to change treatment to another biological treatment regimen (adalimumab)
during their participation in the study. No surgeries were performed during the study period.
Patient Usability eHealth adherence. The overall adherence to using the eHealth program as directed was 74% of survey entries (827 of the 1123 expected) and 72% of FC samples (804 of the 1123 scheduled). Adherence decreased during the intervention period, Figure 5 . 
Patient and Parent Evaluation
All nonexcluded participants answered the evaluation questionnaire (Table 5) . Of the patients, 80% felt they had achieved an increased control over their disease, and 63% felt that they had an improved understanding of their disease. Of the parents, 73% believed their child had an improved understanding of their disease, and 86% felt that they personally had an improved understanding. None of the patients or parents felt unsafe using the eHealth program. Concerning fecal samples, 25% (patients) and 13% (parents) reported that it was a challenge to deliver the samples, whereas 63% of parents "very often" or "often" helped in handling the fecal sample.
DISCUSSION
This study is the first trial of self-managed eHealth for guiding the timing of IFX treatments in children and adolescents with IBD. We have demonstrated that self-managed eHealth can individualize The parent part is presented in italics.
a Percent has been rounded and total can therefore be higher/below 100.
Individualization of Treatment Interval
Strengths of the eHealth program were its careful monitoring of patients and the short delay between a change in the patient's TIBS and the subsequent IFX infusion. The careful monitoring enabled the treatment intervals to be longer than 8 weeks.
The treatment intervals for each patient fluctuated throughout the study and were thus individualized. The potential benefit of an individualized timing of treatment is the tailoring of the amount of medication needed. For patients with treatment intervals .8 weeks, the cumulative doses and costs of medication are lowered. For patients with treatment intervals ,8 weeks, the patient receives a more optimal dosage to keep the disease in remission.
Most of the eHealth participants were treated at intervals of more than 8 weeks. For this reason, some concerns need to be investigated further regarding the precise, long-term impact of extended (.8 wk), or alternating, treatment intervals on the disease course. In the REACH 5 study, treatment intervals were investigated in a randomized trial of IFX responders to either 8-or 12-week intervals. The 8-week interval was found to be preferable to the 12-week interval in terms of clinical response and remission. Nonetheless, among patients with a 12-week interval, 33.3% were maintaining a response and 23.5% were maintaining remission at week 54. We speculate that the eHealth program could be used to identify the patients for whom treatment intervals can be extended.
Another approach to individualizing IFX treatment is to change the IFX doses. Mould et al have proposed the Dashboard system, 24 a decision-supporting software tool, that can guide a physician to adjust dosing regimens based on variables affecting the patient's pharmacokinetics (trough levels of IFX concentration and antibodies, disease activity, weight, and height). This is supported by the Trough Concentration Adapted Infliximab Treatment study (TAXIT) 25 on adult patients with IBD investigated a concentration-based dosing (target IFX trough concentration of 3-7 mg/mL) compared with a clinically based dosing of IFX. The concentration-based regimen had fewer patients with relapse during the 1-year follow-up period. Therefore, a combination of the patient-reported eHealth program and the pharmacokinetic Dashboard could be the optimal way of individualizing IFX treatment intervals and dose regimens while maintaining patient involvement.
Development of antibodies is a concern during episodic IFX treatment, 26 and hence also a theoretical concern when maintenance treatment intervals are prolonged to more than 8 weeks. In the eHealth group, detection of antibodies did not differ significantly from the control group; however, only a small number of patients were included, and hence the risk of a type II error exists, i.e., failing to detect an effect that is present. Similarly, in the adult study of patients with IBD receiving eHealth-scheduled IFX treatment, 17 in which 50% of the treatments were provided at more than 8-week intervals, no difference in the appearance of antibodies was observed. Furthermore, neither did the REACH study find increased development of antibodies in the group receiving treatments every 12 weeks as compared with the group with treatment intervals of 8 weeks.
Patient Usability
Despite requiring a high level of involvement by patients and uncertainty on the date of next infusion, the HRQoL was not affected. The total dropout rate was 13 of 29 patients (45%); hereof did 5 patients (17%) wished to withdraw. The other reasons for dropout were varied, including change of treatments, transfer to adult care, logistical problems, perianal abscess, personal preference, and unsafe adherence. As no systematic tendency to dropout appeared, a proposal to further optimize adherence to the program is not presented.
The overall adherence of patients in registering symptoms on the eHealth homepage and submitting fecal samples was acceptable (74% and 72%, respectively), but adherence did decrease during the study period. A total of 25% of patients commented that it was problematic to submit their fecal samples, whereas 63% of parents responded that they helped in handling the fecal sample. The active patient involvement related to the tight eHealth control might be too demanding for some patients in the longer term.
Strengths and Limitations
The duration of the follow-up and power in this study may not be sufficiently long to assess the long-term impact of fluctuating and extending treatment intervals on the disease course, trough level of IFX, development of IFX antibodies, occurrence of infusion reactions, and loss of response. Further larger and longer studies are necessary to elucidate these issues.
Patients were enrolled from a public hospital, with a dedicated IBD clinic serving a large geographic area representing a diverse patient population. However, selection bias might still have influenced the study as resourceful families are generally more likely to participate in trials. The study was performed at only one IBD center and the number of eligible and included patients was limited, thereby introducing the risk of a type II error. Consequently, we designed this as an intervention, rather than a randomized, study. However, the mean follow-up period per patient was .1.5 years, and a large amount of data was collected from each patient.
The TIBS is based on validated and internationally accepted disease activity indexes/markers (PUCAI/abbrPCDAI + FC). However, the TIBS algorithm is novel, and an evaluation against a golden standard, e.g., endoscopic examination, may be needed to validate the timing of treatments.
The strength of this study is the innovative approach to involving young patients with IBD in the treatment of their disease. Although it is widely agreed that patient empowerment should be supported, no validated template for enhancing young IBD patients' skills currently exists. Based on the patient's evaluation, the eHealth tool might be a promising means of enhancing patient involvement and improving their disease knowledge.
Perspective
We believe that many young and adolescent patients with IBD could benefit from participation in our eHealth program. Two groups of patients should be sought out in particular, namely those patients/families for whom disease knowledge and empowerment are difficult to achieve otherwise, and any difficult-to-treat patients that need individualized and carefully monitored assistance. For scientific use, the program might be useful in clinical trials, where repeated and easily retrieved patient-reported outcomes are required.
CONCLUSIONS
Among children and adolescents with IBD, individualized timing of IFX at treatment intervals between 4 and 12 weeks was made possible using self-managed eHealth monitoring. Although no problems regarding patient safety were observed, the long-term impact on the disease course of fluctuating and extending treatment intervals remains unknown. Patient adherence to the eHealth program was found to be acceptable. Patients and their parents reported an improved knowledge and understanding of the disease course. In the future, our eHealth tool may be used to individualize treatment and to empower patients and their families. Further studies are needed in other and larger populations to clarify the optimal use of eHealth solutions in pediatric IBD.
